TG Therapeutics Inc

TG Therapeutics Inc. a commercial stage biopharmaceutical company focuses on the acquisition development and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome relapsing-remitting disease and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801 a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys as well as collaboration agreement with Checkpoint Therapeutics Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics Inc. was incorporated in 1993 and is based in Morrisville North Carolina.